People with negative responses to a tuberculin skin test a few years after being vaccinated against tuberculosis had a significant, 25% lower risk of developing amyotrophic lateral sclerosis (ALS) in their lifetime, according to a study in Norway. Because a positive reaction is linked to the recruitment of T…
Tuberculosis vaccine screening links T-cell response to ALS risk
Is anyone else bombarded by social media messages to set goals, make New Year’s resolutions, or create a bucket list for 2024? I sure have been. In my pre-ALS days, I heeded the reminders. I looked forward to breaking in a brand-new desk calendar and filling it with my…
Accidents can and will happen. Do you have a plan for when they do? The two accidents I’ve feared the most since being debilitated with ALS are getting scalded in the shower and smashing my toes against the wall or any other object when I’m in my wheelchair. I…
Early data from Phase 2 programs showing that CNM-Au8, an oral therapy candidate for amyotrophic lateral sclerosis (ALS), induced significant reductions in a nerve damage biomarker but did not meet the criteria for accelerated approval at this time, the U.S. Food and Drug Administration (FDA) concluded. Despite the…
After I finished this holiday season’s wreath orders, I moved my wreath-making table out of the dining room back into the garage and put away extra pine cones, bows, and birch bark. The room felt spacious without the clutter, and I told my husband, Todd, “This reminds me of the…
LifeArc, a U.K.-based independent medical research charity, is offering £5 million (about $6 million) to scientists around the world as part of a grant program to tackle motor neuron disease (MND) using repurposed or combined medicines. The program is part of the Motor Neuron Disease Translational Challenge, which…
Scientists at King’s College London have identified the site in motor neurons that appears to be the starting point of dysfunction in amyotrophic lateral sclerosis (ALS) — shedding new light on the workings of the neurodegenerative disease at its earliest stages. “This provides a better understanding of the complex…
What if I told you that eating sugar cookies and cherry pie could help slow down the progression of ALS symptoms? You’d probably say, “Hey Dagmar, you’ve gone bananas!” I know, I know. The suggestion sounds contrary to what we’ve always been told about healthy eating, especially for anyone…
People with amyotrophic lateral sclerosis (ALS) given PrimeC in the PARADIGM Phase 2b trial — and who did not diverge in major ways from the trial’s rules — experienced a significant slowing in disease progression compared with a placebo, the treatment’s developer, NeuroSense Therapeutics, announced. This finding…
Treatment with Relyvrio (sodium phenylbutyrate and taurursodiol) significantly reduced blood levels of neuroinflammatory biomarkers in people with amyotrophic lateral sclerosis (ALS) as early as three months, according to a post hoc analysis of the CENTAUR trial. Data from the Phase 2 study (NCT03127514) demonstrated that reductions in…
Recent Posts
- Scientists find promising 3 drug combo for sporadic ALS using new models
- Small adjustments to a wheelchair can greatly improve comfort
- How ALS patients can show their stripes for Rare Disease Month
- Grants support next generation of ALS researchers in Canada
- ALS research wins big bucks with $313M in new US government funding